Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
therapy
Lung Neoplasms
microRNA
Mesoporous silica nanoparticles
QUIMICA INORGANICA
targeted delivery
MicroRNA
Silicon Dioxide
3. Good health
Gene Expression Regulation, Neoplastic
Mice
MicroRNAs
breast cancer
Breast cancer
QUIMICA ORGANICA
Cell Movement
Cell Line, Tumor
breast cancer, mesoporous silica nanoparticles, microRNA, targeted delivery, therapy
Animals
Nanoparticles
Female
Therapy
Targeted delivery
mesoporous silica nanoparticles
Cell Proliferation
DOI:
10.1021/acsami.3c07541
Publication Date:
2023-08-07T20:45:06Z
AUTHORS (11)
ABSTRACT
Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (67)
CITATIONS (22)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....